Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Epigenetics
HMGA2
Oral squamous cell carcinoma
SMYD3
Tumorigenesis
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
26 05 2023
26 05 2023
Historique:
received:
03
03
2023
accepted:
16
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
Epigenetic dysregulation is essential to the tumorigenesis of oral squamous cell carcinoma (OSCC). SET and MYND domain-containing protein 3 (SMYD3), a histone lysine methyltransferase, is implicated in gene transcription regulation and tumor development. However, the roles of SMYD3 in OSCC initiation are not fully understood. The present study investigated the biological functions and mechanisms involved in the SMYD3-mediated tumorigenesis of OSCC utilizing bioinformatic approaches and validation assays with the aim of informing the development of targeted therapies for OSCC. 429 chromatin regulators were screened by a machine learning approach and aberrant expression of SMYD3 was found to be closely associated with OSCC formation and poor prognosis. Data profiling of single-cell and tissue demonstrated that upregulated SMYD3 significantly correlated with aggressive clinicopathological features of OSCC. Alterations in copy number and DNA methylation patterns may contribute to SMYD3 overexpression. Functional experimental results suggested that SMYD3 enhanced cancer cell stemness and proliferation in vitro and tumor growth in vivo. SMYD3 was observed to bind to the High Mobility Group AT-Hook 2 (HMGA2) promoter and elevated tri-methylation of histone H3 lysine 4 at the corresponding site was responsible for transactivating HMGA2. SMYD3 also was positively linked to HMGA2 expression in OSCC samples. Furthermore, treatment with the SMYD3 chemical inhibitor BCI-121 exerted anti-tumor effects. Histone methyltransferase activity and transcription-potentiating function of SMYD3 were found to be essential for tumorigenesis and the SMYD3-HMGA2 is a potential therapeutic target in OSCC.
Sections du résumé
BACKGROUND
Epigenetic dysregulation is essential to the tumorigenesis of oral squamous cell carcinoma (OSCC). SET and MYND domain-containing protein 3 (SMYD3), a histone lysine methyltransferase, is implicated in gene transcription regulation and tumor development. However, the roles of SMYD3 in OSCC initiation are not fully understood. The present study investigated the biological functions and mechanisms involved in the SMYD3-mediated tumorigenesis of OSCC utilizing bioinformatic approaches and validation assays with the aim of informing the development of targeted therapies for OSCC.
RESULTS
429 chromatin regulators were screened by a machine learning approach and aberrant expression of SMYD3 was found to be closely associated with OSCC formation and poor prognosis. Data profiling of single-cell and tissue demonstrated that upregulated SMYD3 significantly correlated with aggressive clinicopathological features of OSCC. Alterations in copy number and DNA methylation patterns may contribute to SMYD3 overexpression. Functional experimental results suggested that SMYD3 enhanced cancer cell stemness and proliferation in vitro and tumor growth in vivo. SMYD3 was observed to bind to the High Mobility Group AT-Hook 2 (HMGA2) promoter and elevated tri-methylation of histone H3 lysine 4 at the corresponding site was responsible for transactivating HMGA2. SMYD3 also was positively linked to HMGA2 expression in OSCC samples. Furthermore, treatment with the SMYD3 chemical inhibitor BCI-121 exerted anti-tumor effects.
CONCLUSIONS
Histone methyltransferase activity and transcription-potentiating function of SMYD3 were found to be essential for tumorigenesis and the SMYD3-HMGA2 is a potential therapeutic target in OSCC.
Identifiants
pubmed: 37237385
doi: 10.1186/s13148-023-01506-9
pii: 10.1186/s13148-023-01506-9
pmc: PMC10223939
doi:
Substances chimiques
histone H3 trimethyl Lys4
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Histones
0
SMYD3 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2023. The Author(s).
Références
Mol Biol Rep. 2021 Nov;48(11):7499-7508
pubmed: 34510321
Int J Oncol. 2019 Oct;55(4):775-788
pubmed: 31432151
Exp Cell Res. 2022 Sep 1;418(1):113271
pubmed: 35764101
Cell Death Dis. 2022 Sep 3;13(9):763
pubmed: 36057625
Semin Cancer Biol. 2020 Apr;61:71-83
pubmed: 31542510
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Cancer Lett. 2019 Jul 10;454:108-119
pubmed: 30981761
Diagnostics (Basel). 2020 Dec 27;11(1):
pubmed: 33375464
Lab Invest. 2013 Dec;93(12):1331-8
pubmed: 24145240
Cell Death Dis. 2021 Feb 1;12(2):144
pubmed: 33542221
Mol Cancer Res. 2022 May 4;20(5):712-721
pubmed: 35105672
Oncotarget. 2017 Nov 22;8(68):112797-112808
pubmed: 29348866
Cancer Res. 2004 Mar 15;64(6):2024-9
pubmed: 15026339
Cell. 2017 Dec 14;171(7):1573-1588.e28
pubmed: 29224777
Life (Basel). 2021 Dec 04;11(12):
pubmed: 34947873
Nature. 2014 Jun 12;510(7504):283-7
pubmed: 24847881
J Cell Physiol. 2015 Oct;230(10):2447-2460
pubmed: 25728514
Eur J Pharmacol. 2021 Jan 15;891:173757
pubmed: 33249080
Cancer Cell. 2016 Mar 14;29(3):354-366
pubmed: 26908355
Nature. 2019 Nov;575(7784):669-673
pubmed: 31748742
Int J Cancer. 2020 Mar 15;146(6):1553-1567
pubmed: 31503345
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2152-62
pubmed: 18669583
Anticancer Res. 2017 Apr;37(4):1891-1899
pubmed: 28373457
Epigenetics. 2012 Apr;7(4):340-3
pubmed: 22419068
Cancers (Basel). 2020 Jan 06;12(1):
pubmed: 31935919
J Dent Res. 2019 Mar;98(3):268-276
pubmed: 30615537
Int J Mol Sci. 2019 May 19;20(10):
pubmed: 31109142
iScience. 2021 Apr 24;24(5):102473
pubmed: 34113819
Cell Stem Cell. 2020 Aug 6;27(2):238-253.e6
pubmed: 32697949
Nucleic Acids Res. 2019 Feb 20;47(3):1278-1293
pubmed: 30544196
J Cell Physiol. 2018 Nov;233(11):8499-8507
pubmed: 29797575
Cancer Res. 2012 Feb 1;72(3):810-20
pubmed: 22194464
Semin Cancer Biol. 2017 Feb;42:70-80
pubmed: 27554136
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Cell Death Differ. 2022 Nov;29(11):2190-2202
pubmed: 35534546
Nat Cell Biol. 2004 Aug;6(8):731-40
pubmed: 15235609
Clin Cancer Res. 2020 Jan 1;26(1):290-300
pubmed: 31562203
Future Oncol. 2018 Aug;14(18):1825-1834
pubmed: 29969917
J Clin Oncol. 2017 Mar;35(7):734-742
pubmed: 28068175
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):197-205
pubmed: 27742669
EBioMedicine. 2019 Sep;47:44-57
pubmed: 31409573
Oral Oncol. 2019 Nov;98:92-95
pubmed: 31574415
Cell. 2008 Oct 17;135(2):227-39
pubmed: 18957199
Cancer Res. 2007 Mar 15;67(6):2626-31
pubmed: 17363582
Theranostics. 2020 Jul 9;10(19):8721-8743
pubmed: 32754274
STAR Protoc. 2021 Jul 17;2(3):100681
pubmed: 34337446
Oncogene. 2019 Jun;38(25):4948-4961
pubmed: 30842588
J Proteomics. 2013 Jan 14;78:72-82
pubmed: 23182705
Genes (Basel). 2021 Feb 13;12(2):
pubmed: 33668453
Nat Rev Cancer. 2021 Jul;21(7):413-430
pubmed: 34002060
Sci Transl Med. 2023 Feb;15(681):eabq6024
pubmed: 36724242
Cancer. 2018 Oct 15;124(20):4072-4079
pubmed: 30335190
Cancer Res. 2016 Jun 15;76(12):3446-50
pubmed: 27256564
Asian Pac J Cancer Prev. 2014;15(20):8549-56
pubmed: 25374166
Mol Ther. 2020 Oct 7;28(10):2177-2190
pubmed: 32621798
Stem Cells Int. 2017;2017:5619472
pubmed: 28473858
Clin Cancer Res. 2017 Jun 15;23(12):3120-3128
pubmed: 27965308
Cancer Lett. 2018 Aug 28;430:11-24
pubmed: 29746925
Cancer Discov. 2022 Sep 2;12(9):2158-2179
pubmed: 35819319
Clin Epigenetics. 2021 Feb 26;13(1):45
pubmed: 33637115
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1536-1541
pubmed: 28137832
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Cell Biosci. 2014 Aug 19;4:45
pubmed: 25949794
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):3981-3989
pubmed: 34156675
Nucleic Acids Res. 2018 Jan 4;46(D1):D918-D924
pubmed: 29036683
Cell Rep. 2021 Feb 23;34(8):108769
pubmed: 33626351
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397
Cancer Res. 2015 Jun 15;75(12):2553-65
pubmed: 25858147
PeerJ. 2020 Jun 17;8:e9393
pubmed: 32596058
Int J Biol Sci. 2021 Aug 12;17(13):3476-3492
pubmed: 34512160
Nucleic Acids Res. 2021 Jul 2;49(W1):W317-W325
pubmed: 34086934
Biochem Biophys Res Commun. 2015 Sep 18;465(2):194-9
pubmed: 26241672
Oncoimmunology. 2021 Jun 23;10(1):1938890
pubmed: 34221701